Author
A. D. Lander
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2020-2024 · peak 2/yrCo-Author Collaboration Network
10 top collaborators · 20 mutual co-author links4 papers
Recent·Most cited
Uncovering Minimal Pathways in Melanoma Initiation
H. Xiao, J. Shiu, C.-F. Chen, J. Wu, P. Zhou, S. S. Telang, R. Ruiz-Vega, A. D. Lander, A. K. Ganesan
This study identifies LNM cells as a pre-malignant state in melanoma initiation, showing they pre-exist in normal skin, expand with Braf activation, and contribute to drug resistance.
bioRxiv · Dec 8, 2023Cancer Biology
Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes
R. Ruiz-Vega, C.-F. Chen, E. Razzak, P. Vasudeva, T. Krasieva, J. Shiu, M. G. Caldwell, H. Yan, J. Lowengrub, A. K. Ganesan, A. D. Lander
The paper investigates nevus growth arrest using a mouse model and finds that collective cell behavior, not cell-autonomous senescence, explains nevus size control.
bioRxiv · Jul 14, 2020Cancer Biology
NTR 2.0: a rationally-engineered prodrug converting enzyme with substantially enhanced efficacy for targeted cell ablation
A. v. Sharrock, T. S. Mulligan, K. R. Hall, E. M. Williams, D. T. White, L. Zhang, F. Matthews, S. Nimmagadda, S. Washington, K. Le, D. Meir-Levi, O. L. Cox, M. T. Saxena, A. Calof, M. E. Lopez-Burks, , J. S. Mumm
This paper describes the development of NTR 2.0, a modified nitroreductase with significantly improved efficacy for targeted cell ablation using metronidazole.
bioRxiv · May 22, 2020Cell Biology